170 related articles for article (PubMed ID: 12297238)
1. Vaginal wetness: an underestimated problem experienced by progestogen injectable contraceptive users in South Africa.
Smit J; McFadyen L; Zuma K; Preston-Whyte E
Soc Sci Med; 2002 Nov; 55(9):1511-22. PubMed ID: 12297238
[TBL] [Abstract][Full Text] [Related]
2. Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa.
Beksinska ME; Rees HV
Afr J Reprod Health; 2001 Dec; 5(3):84-8. PubMed ID: 12471932
[TBL] [Abstract][Full Text] [Related]
3. A five year review of the complications of progestogen only injectable contraceptive at the University of Port-Harcourt Teaching Hospital.
Ojule JD; Oriji VK; Okongwu C
Niger J Med; 2010; 19(1):87-95. PubMed ID: 20232762
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with injectable progestogen- only contraceptives at University of Ilorin teaching hospital: a five year review.
Balogun OR; Raji HO
Niger Postgrad Med J; 2009 Dec; 16(4):260-3. PubMed ID: 20037621
[TBL] [Abstract][Full Text] [Related]
5. Once-a-month injectable contraceptives: efficacy and reasons for discontinuation.
Koetsawang S
Contraception; 1994 Apr; 49(4):387-98. PubMed ID: 8013221
[TBL] [Abstract][Full Text] [Related]
6. Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa.
Smit J; Gray A; McFadyen L; Zuma K
BMC Health Serv Res; 2001; 1():4. PubMed ID: 11401729
[TBL] [Abstract][Full Text] [Related]
7. Progestogen-only injectable contraceptive: experience of women in Osogbo, southwestern Nigeria.
Adeyemi AS; Adekanle DA
Ann Afr Med; 2012; 11(1):27-31. PubMed ID: 22199044
[TBL] [Abstract][Full Text] [Related]
8. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
9. A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives.
Fraser IS
Contraception; 1983 Oct; 28(4):385-97. PubMed ID: 6230212
[TBL] [Abstract][Full Text] [Related]
10. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting.
Bull World Health Organ; 1993; 71(6):677-89. PubMed ID: 8313486
[TBL] [Abstract][Full Text] [Related]
11. Once-a-month injectable contraceptives.
d'Arcangues C
World Health Forum; 1993; 14(4):439-40. PubMed ID: 8185807
[TBL] [Abstract][Full Text] [Related]
12. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
[TBL] [Abstract][Full Text] [Related]
13. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.
Hofmeyr GJ; Singata-Madliki M; Lawrie TA; Bergel E; Temmerman M
Reprod Health; 2016 Apr; 13():42. PubMed ID: 27091008
[TBL] [Abstract][Full Text] [Related]
14. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. From the World Health Organization Special Programme for Research, Development, and Research Training in Human Reproduction; Task Force on Long-acting Systemic Agents for the Regulation of Fertility.
Gray RH; Parker RA; Diethelm P
Br J Obstet Gynaecol; 1981 Mar; 88(3):317-21. PubMed ID: 7008825
[TBL] [Abstract][Full Text] [Related]
15. Acceptability of once-a-month injectable contraceptives Cyclofem and Mesigyna: focus group discussion.
el Nahal N; Hassan EO; el Houssinie M
Contraception; 1999 Jun; 59(6):369-75. PubMed ID: 10518231
[TBL] [Abstract][Full Text] [Related]
16. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and sid effects.
Sang GW; Shao QX; Ge RS; Ge JL; Chen JK; Song S; Fang KJ; He ML; Luo SY; Chen SF
Contraception; 1995 Mar; 51(3):167-83. PubMed ID: 7621685
[TBL] [Abstract][Full Text] [Related]
17. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
Draper BH; Morroni C; Hoffman M; Smit J; Beksinska M; Hapgood J; Van der Merwe L
Cochrane Database Syst Rev; 2006 Jul; (3):CD005214. PubMed ID: 16856087
[TBL] [Abstract][Full Text] [Related]
18. Injectable contraceptives: a worldwide perspective.
Affandi B
J Fam Plann Reprod Health Care; 2002 Jan; 28(1):3-4. PubMed ID: 16259804
[No Abstract] [Full Text] [Related]
19. Bone status after cessation of use of injectable progestin contraceptives.
Rosenberg L; Zhang Y; Constant D; Cooper D; Kalla AA; Micklesfield L; Hoffman M
Contraception; 2007 Dec; 76(6):425-31. PubMed ID: 18061699
[TBL] [Abstract][Full Text] [Related]
20. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
